Microbiotica Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Microbiotica's estimated annual revenue is currently $11M per year.(i)
  • Microbiotica's estimated revenue per employee is $224,592

Employee Data

  • Microbiotica has 49 Employees.(i)
  • Microbiotica grew their employee count by -11% last year.

Microbiotica's People

NameTitleEmail/Phone
1
Co-founder and CSOReveal Email/Phone
2
CMOReveal Email/Phone
3
CEOReveal Email/Phone
4
VP Clinical DevelopmentReveal Email/Phone
5
SVP ResearchReveal Email/Phone
6
VP Pre-Clinical DevelopmentReveal Email/Phone
7
VP Operations and Company SecretaryReveal Email/Phone
8
Director, InformaticsReveal Email/Phone
9
Clinical Programme DirectorReveal Email/Phone
10
Clinical Project DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M864%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M68030%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M509512%N/AN/A
Add Company

What Is Microbiotica?

Microbiotica is transforming personalised medicine with leading microbiome science, identifying gut bacteria linked to patient phenotype with unprecedented precision for the discovery of novel microbiome-based medicines and biomarkers of drug response. Microbiotica was spun out of Trevor Lawley's Lab at the Wellcome Sanger Institute and is founded on a unique pipeline for culturing and genomically characterising the entirety of the bacteria in the human gut for the first time. It has the world's largest microbiome genome database and culture collection, a suite of translational in vitro and animal models, and state of the art bioinformatics and AI. The company has a focus on IBD and Immuno-Oncology, and a program in C. difficile which is spearheading innovation in development of live bacterial products.

keywords:N/A

N/A

Total Funding

49

Number of Employees

$11M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Microbiotica News

2022-03-22 - Microbiotica aims to rethink care for cancer and ulcerative ...

Microbiotica Ltd. of Cambridge, U.K., has raised £50 million ($67 million) in series B funding as the company aims to test its...

2022-03-22 - Microbiotica Closes $67M Series B Financing

Microbiotica, a Cambridge, UK-based player in discovering and developing microbiome-based therapeutics and biomarkers, closed a £50m ($67m)...

2022-03-22 - Microbiotica Raises £50m ($67m) to Advance Pipeline of ...

Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing...

2021-06-24 - Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology 24-06-2021 Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that its Live Bacterial Therapeutic (LBT) MB097 is now in pre-clinical ...

2021-06-24 - Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology 24-06-2021 Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that its Live Bacterial Therapeutic (LBT) MB097 is now in pre-clinical ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M49-6%N/A
#2
$5.2M49-2%$4M
#3
$9.1M49-8%N/A
#4
$9.1M49-8%N/A
#5
$5.1M4936%N/A